Clinical Trial – Blinatumomab – Non-Hodgkin Lymphoma

Massachusetts General Hospital is running a clinical trial to test a drug called Blinatumomab to treat Non-Hodgkin Lymphoma. This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).

The drug is Blinatumomab.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Actual Study Start Date : August 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2023

For enrollment please visit www.clinicaltrials.gov.

 

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.